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Objective: The function of the exocrine pancreas is decreased in patients with type 1 diabetes
but it is not known when this defect develops. The current study set out to determine whether
the reduced exocrine function becomes manifest after the initiation of islet autoimmunity.
Methods: The study was nested in the prospective Type 1 Diabetes Prediction and Prevention
study where children with human leukocyte antigen (HLA)-conferred susceptibility are
observed from birth. Elastase-1 levels were analyzed from stool samples collected at the time
of seroconversion to islet autoantibody positivity and at diagnosis of type 1 diabetes, as well as
from samples taken from matched control children of similar age.
Results: Elastase levels were lower in case children at the time of the diagnosis of diabetes
when compared to the control children. However, elastase concentrations did not differ
between cases and controls at the time when autoantibodies appeared.
Conclusion: The results suggest that the defect in the exocrine function develops after the
appearance of islet autoantibodies. Further studies are needed to assess whether reduced elas-
tase levels predict rapid progression of islet autoimmunity to clinical disease.
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1 | INTRODUCTION
Previous studies have suggested that the function of the exocrine
pancreas is impaired in 43% to 80% of patients with type
1 diabetes.1–3 However, the underlying mechanisms are poorly
understood, and several hypotheses have been put forward, including
an autoimmune process against exocrine pancreas, a decreased tro-
phic effect of insulin on the exocrine pancreas, microangiopathy, ath-
erosclerosis and diabetic neuropathy.4 It has also been hypothesized
that pancreatic insufficiency could be related to a specific subtype of
diabetes in which the whole organ is affected (type 3c diabetes).5,6
Recent studies have provided new insights into the disease pro-
cess affecting pancreas tissue in type 1 diabetes. One of the key find-
ings is that the size of the whole organ is clearly reduced, and this
decrease can be seen already within months after the diagnosis of
type 1 diabetes.7 Another study carried out in the nPOD (Network
for Pancreatic Organ Donors with Diabetes) collection showed that
the weight of the pancreas was reduced not only in patients with
type 1 diabetes but also in prediabetic individuals who tested positive
for islet autoantibodies.8 In addition, studies in the nPOD collection
have shown that exocrine tissue is affected by inflammation.9–11
The present study evaluates whether elastase concentrations in
stools, as one of the most widely used biomarker of the function of
exocrine pancreas, is reduced in children with newly diagnosed type
1 diabetes, and whether a possible reduction can be observed already
at the early preclinical stage of the disease, close to the time when
the first autoantibodies appear.
2 | METHODS
2.1 | Study design
The study cohort included 81 case children who had either newly
diagnosed type 1 diabetes (n = 28) or who were non-diabetic but
positive for multiple islet autoantibodies (n = 53). The autoantibody
positive children were recruited in the Type 1 Diabetes Prediction
and Prevention (DIPP) birth cohort study, which observes children
with increased human leukocyte antigen (HLA)-conferred susceptibil-
ity to type 1 diabetes from birth in 3 regions in Finland. Serum and
stool samples have been collected regularly during the follow-up and
islet cell antibodies (ICA), insulin autoantibodies (IAA), glutamic acid
decarboxylase antibodies (GADA) and insulinoma-associated protein
2 antibodies (IA-2A) have been analyzed from all follow-up sera as
described previously.12
Study subjects were selected from the DIPP cohort on the basis
of availability of a stool sample taken at the time when the first auto-
antibodies were detected and/or at the time of diagnosis of type
1 diabetes. The participants were born between 1996 and 2008, 63%
were boys and the median age at autoantibody seroconversion was
1.3 years (range 0.4-4.1 years). All non-diabetic case children (n = 53)
were positive for at least 2 of the tested autoantibodies and
41 (77%) had progressed to clinical type 1 diabetes. Their median age
at the time of diagnosis was 4.9 years (range 1.6-13.0 years). The
DIPP children carried HLA risk alleles for type 1 diabetes (HLA-
DQB1*02/*0302, DQB1*0302/x [x 6¼ *02, *0301 or *0602] or
DQB1*02/y-DQA1*05/z [y 6¼ *0301, *0302,*0602,*0603; z 6¼
*0201] genotypes). A series of children with newly diagnosed type
1 diabetes (n = 19) was in addition available from Tampere University
Hospital in Finland. These children were born between 1990 and
2003, 68% were boys and the median age at diagnosis was 9.2 years
(range 1.4-14.5 years). One non-diabetic and islet autoantibody nega-
tive control child was selected from the DIPP cohort for each case
child and matched for calendar time of birth ( 6 months), sex, date
of sampling ( 2 months), city of residence and HLA-DQ alleles
(described above). The demographics of study subjects are summa-
rized in Table S1, Supporting Information.
All study subjects had written parental consent to take part in
the study. The Ethics Committees of Oulu, Tampere and Turku Uni-
versity Hospitals in Finland have approved the DIPP study protocol.
2.2 | Measurement of stool elastase concentration
A stool sample was available for elastase analyses from the time of
autoantibody seroconversion from 53 case children (samples taken
from 11 weeks before to 14 weeks after the first autoantibody posi-
tive serum) and from the time of diabetes diagnosis from 28 case
children (taken from 9 weeks before to 1 week after diagnosis).
Three children had samples from both time-points. In addition, long
series of stool samples were available from 3 additional children to
evaluate changes in elastase levels over time (mean 11 samples per
child). All stool samples were stored at –20C to −70C until
analyzed.
Pancreatic elastase-1 (PE-1) was measured using a commercial
enzyme-linked immunosorbent assay according to the manufacturer’s
protocol (ScheBo Biotech, Giessen, Germany). Stool specimens were
prepared by the E1 Quick-Prep device (ScheBo Biotech, Giessen,
Germany) and the sample was diluted 56-fold before analyses. The
results were expressed in μg/g of stool, and values less than
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200 μg/g were considered as markers of exocrine pancreatic insuffi-
ciency and values less than 100 μg/g as markers of severe insuffi-
ciency in both case and control children according to the
manufacturer’s instructions.
2.3 | Statistical methods
Statistical analysis was performed using the Student’s t-test for
2 groups and the χ2 test. Assumptions were that the response vari-
able, elastase concentration, is normally distributed and variances in
both groups are similar. Log transformation was performed to get
variable normally distributed. Levene’s test for equality of variances
and t-test was performed for log transformed data using R 3.2.2
(www.r-project.org). χ2 test was performed by SPSS (IBM SPSS Sta-
tistics for Windows; version 23.0. Armonk, NY, USA). For all statisti-
cal tests, a significance level of .05 was applied (2-sided, P < .05).
3 | RESULTS
Elastase levels did not differ between the 53 case and 53 control chil-
dren at the time of islet autoantibody seroconversion (mean 1013
versus 1203 μg/g; median 738 versus 877 μg/g, P = .149; Figure 1A).
Low elastase levels (< 200 μg/g of stool) were seen in 5 (9.4%) of the
case children and in 1 (1.9%) of their controls (P = .093).
Elastase levels were significantly lower in stool samples collected
from the 28 newly diagnosed type 1 diabetic patients compared to
their matched controls (mean 355 versus 828 μg/g; median 230 ver-
sus 483 μg/g, P = .0006; Figure 1B). Low levels (<200 μg/g of stool)
were seen in 11 (39.3%) of the case children and in 2 (7.1%) con-
trols (P = .004).
Among the 41 children who progressed to clinical diabetes low
elastase levels at autoantibody seroconversion did not explain the
speed of progression even though a tendency for faster progression
was seen (P = .1033 in linear regression analysis). Five of them (12%)
had initially low elastase levels (< 200 μg/g), and they progressed to
diabetes in 61.3 months (mean) compared to 48.1 months in children
with higher elastase levels.
A large set of follow-up stool samples was available from 3 children
ranging from the age of 3 to 6 months to the diagnosis of diabetes. A
decreasing trend was seen in elastase levels towards diabetes in all of
them. In 1 patient, elastase levels decreased gradually showing consid-
erable fluctuation (Figure 2A). In another patient elastase levels rapidly
declined soon after autoantibody seroconversion and stayed at low
levels until diabetes was diagnosed (Figure 2B). In the third patient, the
elastase concentration decreased sharply at 3.5 months of age already
before islet autoantibody seroconversion and remained at low levels
until clinical diabetes was diagnosed (Figure 2C).
4 | DISCUSSION
This is the first study where the exocrine function of the pancreas
has been evaluated during the early preclinical stage of type 1 diabe-
tes by measuring elastase levels in stool samples. The results suggest
that while the exocrine function is clearly decreased at the diagnosis
of clinical type 1 diabetes this decrease is not present at the time
when islet autoantibodies appear. This suggests that in most cases
the defect in the function of the exocrine pancreas develops after
the initiation of islet autoimmunity. This indicates that this defect is
linked to the diabetic disease process per se and is not an inherited
character of diabetic patients. The few cases where several longitudi-
nal stool samples were available from different stages of the beta-cell
damaging process showed marked individual variation in the decrease
of elastase levels over time suggesting that in some children the
levels may decrease steeply even within a few months, while in some
others this decrease may emerge gradually showing considerable fluc-
tuation. In 1 case, a rapid decrease occurred already some months
before the detection of islet autoantibodies. However, since the
autoantibodies were measured from sera collected with 3 to
6 months interval, the decrease in elastase occurred probably at the
same time when autoantibodies truly appeared. Altogether, these
results suggest that repeated measurements of stool elastase levels
offer a feasible way to identify a significant part of children whose
pancreas function decreases prior or after the diagnosis of type 1 dia-
betes. As a non-invasive method this could be used as a primary
screening tool in young children, and be supplemented by confirma-
tory assays such as measurement of serum lipase levels.13 The mea-
surement of elastase concentrations in stools by enzyme-linked
immunosorbent assay (EIA) has long been used to evaluate exocrine
pancreatic function in clinical practice.14,15 Elastase is synthesized by
the acinar cells along with the other digestive enzymes, and it is not
significantly degraded during intestinal transit. Its concentration in
human feces is about 5-to 6-fold higher than in pancreatic-duodenal
juice. It is also stable in stool samples for up to 1 week at room tem-
perature13 and is not degraded during a long-term storage at
−20C.16,17 The good stability during storage at freezer was also sug-
gested by our observation that elastase concentrations did not differ
FIGURE 1 Pancreatic elastase-1 concentration levels in stool
samples in children with diabetes-associated autoantibodies (A) and
in children with type 1 diabetes (B) and in their matched controls.
Box plots represent the data after base-e log transformation. Each
box plot represents the median (horizontal line), interquartile range
and the lowest and highest values (error bars). Values of individual
children are shown as circles
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between samples with the longest and shortest storage time (median
elastase levels 1244 versus 1369 μg/g, P = .8238). This comparison
was done using only samples collected from the control children.
Our results are in line with previous observations showing
that the exocrine pancreas of type 1 diabetic patients is affected
by an inflammatory process and fibrosis18 and that this process
can start already before type 1 diabetes is diagnosed. Recent
studies have also shown that the size of the whole organ is
decreased both in patients and in autoantibody-positive predia-
betic individuals.7,8 Altogether, these studies suggest that type
1 diabetes is not only a disease of the beta-cells, but a disease
which may affect the whole pancreas. It is unclear whether the
FIGURE 2 Pancreatic elastase-1 concentration in serial stool samples collected from 3 children who were followed from birth and turned
positive for islet autoantibodies and progressed to clinical type 1 diabetes (panels A, B and C). The time of the collection of the first islet
autoantibody positive serum and the time of the diagnosis of type 1 diabetes are marked by white and black arrows, respectively. ,
pancreatic elastase-1; , insulin autoantibodies (IAA); , islet cell autoantibodies (ICA); , glutamic acid decarboxylase autoantibodies
(GADA); , insulinoma-associated protein 2 antibodies (IA-2A). Cutoffs of autoantibody units are described in Table S1, Supporting
Information
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exocrine dysfunction is caused by the same mechanisms as the
beta-cell damaging process or if it is secondary to endocrine dam-
age and/or inflammatory changes.
The observed decrease in elastase levels in 40% of the patients
with newly diagnosed type 1 diabetes is in line with previous publica-
tions.13 Thus, even if the average elastase levels are lower in patients
than in controls only few of them may have clinically significant pan-
creas insufficiency. In any case, the present study clearly shows that
elastase is associated with advanced beta-cell damage in young chil-
dren. As the study included only young children and the majority of
the samples were collected before the age of 3 years, it was not pos-
sible to study the occurrence of pancreatic insufficiency in older
children.
In conclusion, the results suggest that a defect in exocrine func-
tion develops in about 40% of the patients during the progression of
islet autoimmunity to clinical type 1 diabetes. This may open possibil-
ities to use stool elastase levels as a biomarker for the progression of
the beta-cell damaging process. As the method is simple, non-invasive
and technically easy to perform, further studies are indicated to find
out whether it could offer a new tool to predict the development of
type 1 diabetes in autoantibody-positive individuals.
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